$CDTX News
Last published 11mo ago
- 11mo agoCDTXCidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk PopulationsGlobeNewswireTarget enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need for additional enrollment during Southern Hemisphere flu season SAN DIEGO,
- 12mo agoCDTXMRKMerck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral AgentBusiness WireCD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with
- 1y agoCDTXCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswireAnnounced expanded and accelerated Phase 3 Plan for CD388, its non-vaccine influenza preventative therapeuticEnrolled and dosed first patients in Phase 3 ANCHOR study; target enrollment on track for completion in the
- 1y agoCDTXCidara Therapeutics to Participate in November Investor ConferencesGlobeNewswireSAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025GlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025GlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025GlobeNewswireSAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025GlobeNewswireSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Present at 10th ESWI Influenza Conference 2025GlobeNewswireSAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza PreventionGlobeNewswireSAN DIEGO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative TherapeuticGlobeNewswireSAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk PopulationsGlobeNewswire- Phase 3 study expected to enroll 6,000 participants starting in the Northern Hemisphere - Participants will include adults over 65 years of age in addition to individuals with high-risk co-morbidities and immune compromised status
- 1y agoCDTXCidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal InfluenzaGlobeNewswire- Update based on FDA End-of- Phase 2 meeting outcome - Phase 3 study start accelerated by six months, in time for the fall 2025 Northern Hemisphere flu season - A single Phase 3 trial of CD388, if successful, may
- 1y agoCDTXCidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingGlobeNewswire- Efficacy and safety results from successful NAVIGATE Phase 2b trial of CD388 for prevention of influenza illness featured in late-breaking presentation - Preclinical data demonstrating potential efficacy of CD388 to
- 1y agoCDTXCidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoCDTXCidara Therapeutics to Participate in September Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 MeetingGlobeNewswireSAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCDTXCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial ResultsGlobeNewswirePhase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groupsEnd of Phase 2 meeting request submitted to the U.S. Food and
- 1y agoCDTXCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025GlobeNewswireSAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® IndexesGlobeNewswireSAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireSAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
- 1y agoCDTXCidara Announces Pricing of Upsized Public Offering of Common StockGlobeNewswireSAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
- 1y agoCDTXCidara Announces Proposed Public Offering of Common StockGlobeNewswireSAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. ("Cidara") (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics,
- 1y agoCDTXCidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025GlobeNewswireSAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)
- 1y agoCDTXCidara Therapeutics to Participate in Two Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsGlobeNewswireData cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a
- 1y agoCDTXCidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical DevelopmentGlobeNewswireSAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Participate in The Citizens Life Sciences ConferenceGlobeNewswireSAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today
- 1y agoCDTXCidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025GlobeNewswireSAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXPHATPhathom Pharmaceuticals Appoints Ted Schroeder to its Board of DirectorsGlobeNewswireFLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases,
- 1y agoCDTXCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewswireSAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and ResponseGlobeNewswireSAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025GlobeNewswireSAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today
- 1y agoCDTXCidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature MicrobiologyGlobeNewswireData highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a
- 1y agoCDTXCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireCompleted enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity
- 1y agoCDTXCidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial OfficerGlobeNewswireSAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 1y agoCDTXCidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech ConferenceGlobeNewswireSAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 1y agoCDTXCidara Therapeutics Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal InfluenzaGlobeNewswireSAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 1y agoCDTXCidara Therapeutics Announces $105 Million Private PlacementGlobeNewswireSAN DIEGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 1y agoCDTXCidara Therapeutics to Participate in Evercore 7th Annual HealthCONx ConferenceGlobeNewswireSAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswireSAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)
- 2y agoCDTXCidara Therapeutics to Participate in Two Upcoming November Investor ConferencesGlobeNewswireSAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024GlobeNewswireSAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswireSAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza ConferenceGlobeNewswireSAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal InfluenzaGlobeNewswireSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed
- 2y agoCDTXCidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease ExpertsGlobeNewswireSAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed